In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
BackgroundTo characterize the clinical and pathological features and survival of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer in China.MethodsThe China National Cancer Center database was used to identify 1,433 metastatic breast cancer patients with HER2-negative d...
Main Authors: | Yiqun Li, Nilupai Abudureheiyimu, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, Qiao Li, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma, Binghe Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.774577/full |
Similar Items
-
Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
by: Xiuwen Guan, et al.
Published: (2023-02-01) -
Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China
by: Yiqun Li, et al.
Published: (2022-02-01) -
The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI
by: Ismail Saygin, et al.
Published: (2022-01-01) -
Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
by: Maiyue He, et al.
Published: (2023-12-01) -
Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
by: Hangcheng Xu, et al.
Published: (2022-06-01)